The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10, NCT02592746).
 
Yeon Hee Park
Honoraria - Merck; Novartis; Pfizer
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca; Eisai; Pfizer
Travel, Accommodations, Expenses - Merck; Novartis
 
Tae Yong Kim
Consulting or Advisory Role - Eisai; Samsung Bioepis
Speakers' Bureau - Eisai; Roche; Samsung Bioepis; Sanofi/Aventis
 
Gun Min Kim
No Relationships to Disclose
 
Kyung Hae Jung
No Relationships to Disclose
 
Seok Yun Kang
No Relationships to Disclose
 
In Hae Park
No Relationships to Disclose
 
Jee Hyun Kim
No Relationships to Disclose
 
Kyoung Eun Lee
No Relationships to Disclose
 
Hee Kyung Ahn
Consulting or Advisory Role - AstraZeneca; Menarini; Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Eisai
Research Funding - Samyang
 
Moon Hee Lee
No Relationships to Disclose
 
Hee Jun Kim
No Relationships to Disclose
 
Han Jo Kim
No Relationships to Disclose
 
Jong In Lee
No Relationships to Disclose
 
Su-Jin Koh
No Relationships to Disclose
 
Ji-Yeon Kim
No Relationships to Disclose
 
Kyung-Hun Lee
Honoraria - AstraZeneca; Roche
Consulting or Advisory Role - Bayer; Eisai; Ono Pharmaceutical; Samsung Bioepis
 
Joohyuk Sohn
No Relationships to Disclose
 
Sung-Bae Kim
Consulting or Advisory Role - Enzychem Lifesciences (Inst); Lilly (Inst); Novartis (Inst); Odonate Therapeutics (Inst)
Research Funding - Dongkook Pharma (Inst); Genzyme (Inst); Novartis (Inst)
 
Young-Hyuck Im
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - AstraZeneca; Eisai; Novartis; Pfizer; Roche/Genentech
Research Funding - AstraZeneca; Pfizer
Travel, Accommodations, Expenses - MSD Oncology; Novartis; Roche/Genentech
Other Relationship - Roche